Rephine is delighted to announce the purchase of the business via a management buy-out, by a team comprising the existing senior managers together with a new CEO, CFO and Chair, backed by Kester Capital, a London-based private equity investor and primary buyout specialist. Headquartered in Stevenage, and with offices in India and Turkey, Rephine is …
Kester Capital backs management buy-out of Rephine Read More »
It’s been a difficult year for many biopharma companies and perhaps even more so for clinical research organisations, with Covid-19 forcing the postponement or even cancellation of many if not most clinical trials. It is however important to keep a finger on the pulse of the other imminent regulatory changes that will impact work programmes …
The global disruption caused by the pandemic meant regulatory plans for 2020 needed to be delayed to give the life sciences industry and authorities breathing room. However, it is important to keep up to date with imminent regulatory changes that will impact the industry. In my last blog in this series (Getting Ready for the …
In early December, the EMA announced that it had been hit by a cyber-attack and that documents related to the Pfizer-BioNTech Covid-19 vaccines had been accessed. The agency issued a brief announcement after the attack to say a full investigation had been launched but provided no further details. The incident is a reminder to both …
